I-Mab price target lowered to $25 from $30 at Piper Sandler

Piper Sandler analyst Joseph Catanzaro lowered the firm’s price target on I-Mab to $25 from $30 and keeps an Overweight rating on the shares. The company reported fiscal 2022 earnings and provided a pipeline update with progress across the portfolio, the analyst tells investors in a research note. The firm says 2023 will bring a number of data readouts for I-Mab.